- President Trump has been given two experimental treatments and a powerful steroid to treat COVID-19
- Pelosi questioned Trump’s recent behavior, saying he appears to be in an “altered state”
- Trump responded, calling Pelosi crazy
Democratic lawmakers say they are concerned about President Donald Trump’s mental state following treatment for COVID-19 and introduced legislation Friday to create a commission to determine if the president is fit for office under the 25th Amendment to the U.S. Constitution.
The discussion comes just 24 days before the Nov.3 election.
Rep. Jamie Raskin, D-Md., said there never has been a good time to set up the commission but the current situation has focused everyone’s attention.
House Speaker Nancy Pelosi denied this is just another attempt by Democrats to go around the voting process.
“This is not about President Trump. He will face the judgment of voters. But he shows the need to create
The key provision is the 25th Amendment. The original Constitution provided that the vice president steps in when the president is incapacitated, but it said nothing about how the president’s incapacity was supposed to be determined. As a result, we have had long stretches (when President James Garfield was shot; when President Woodrow Wilson had a stroke) where the vice president should have been in charge but instead the president’s staff or spouse ruled. Enacted in the 1960s after John F. Kennedy was assassinated and at the height of the Cold War, the 25th Amendment finally provided a clear process, with the aim of ensuring that there is always a hand at the helm.
Section 3 of the amendment allows the president to transfer power voluntarily to the vice president. To do this, Trump would send formal notice to the speaker of the House and president pro tempore of the
CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it will present multiple posters on the company’s ongoing studies in patients with facioscapulohumeral muscular dystrophy (FSHD) during the 25th International Congress of the World Muscle Society.
“FSHD is a serious and debilitating disease for which there are currently no approved therapies,” said Diego Cadavid, MD, Fulcrum’s senior vice president, clinical development. “We are pleased to share these data at this important scientific meeting as we continue to pursue losmapimod as a potential treatment for FSHD by addressing the root cause of the disease. We greatly appreciate the patients who have participated in our trials and the support we have received from key opinion leaders and investigators.”
During the Virtual Poster Session today, October 1, 2020 from 12:30pm
STRASBOURG, Pa. and PHILADELPHIA, Sept. 28, 2020 /PRNewswire/ — Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced today that the company will present two posters containing data on the natural history of Myotubular and Centronuclear Myopathies (CNM) at the 25th Annual Congress of the World Muscle Society (WMS25). The WMS25 meeting is being held in a virtual format.
Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 (DNM2), for the treatment of CNM. DYN101 is currently being evaluated in a Phase 1/2 clinical study, ‘UNITE-CNM’ (DYN101-C101), at multiple clinical sites in Europe.
Details of the poster presentations are listed below:
Poster Abstract: # LSP (late submitted poster) 6
Title: Hierarchical Bayesian model of disease progression in centronuclear myopathy allows to demonstrate treatment efficacy with a small sample size